Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

A Systematic Review of Secretome-Based Therapies for Alzheimer's Disease: Bridging the Preclinical and Clinical Gap

Version 1 : Received: 5 June 2024 / Approved: 5 June 2024 / Online: 5 June 2024 (12:56:40 CEST)

How to cite: Hambarsari, Y.; Suroto, S.; Mirawati, D. K.; Soetrisno, S.; Wasita, B.; Widyaningsih, V.; Pamungkasari, E. P.; Subandi, S.; Danuaji, R.; Hamidi, B. L.; Hutabarat, E. A. J.; Ristinawati, I.; Tejomukti, T.; Tedjo, R. A. A.; Asaduddin, A. H.; Hafizhan, M.; Putra, S. E. A Systematic Review of Secretome-Based Therapies for Alzheimer's Disease: Bridging the Preclinical and Clinical Gap. Preprints 2024, 2024060273. https://doi.org/10.20944/preprints202406.0273.v1 Hambarsari, Y.; Suroto, S.; Mirawati, D. K.; Soetrisno, S.; Wasita, B.; Widyaningsih, V.; Pamungkasari, E. P.; Subandi, S.; Danuaji, R.; Hamidi, B. L.; Hutabarat, E. A. J.; Ristinawati, I.; Tejomukti, T.; Tedjo, R. A. A.; Asaduddin, A. H.; Hafizhan, M.; Putra, S. E. A Systematic Review of Secretome-Based Therapies for Alzheimer's Disease: Bridging the Preclinical and Clinical Gap. Preprints 2024, 2024060273. https://doi.org/10.20944/preprints202406.0273.v1

Abstract

Background: Alzheimer's Disease (AD) is a progressive neurodegenerative disorder with a rapidly increasing prevalence. Current therapeutic options primarily manage symptoms, not modifying the disease. Secretome-based therapies have emerged as a promising avenue for AD treatment in targeting multiple pathways and promoting neuroprotection and regeneration. This systematic review evaluated the preclinical and clinical evidences for secretome-based therapies in AD.Methods: A systematic search was conducted across Scopus, PubMed, ScienceDirect, and Cochrane Library. The SYRCLE risk of bias (RoB) tool was used for preclinical studies and Cochrane RoB 2.0 for clinical studies. We performed qualitative analysis of study results.Results: Included 21 in vivo studies and 2 clinical trials revealed promising outcomes of treatments involving secretomes, exosomes, and extracellular vesicles from different cell sources. The therapies could reduce amyloid plaque load, reactive gliosis, and enhance neuronal density. These findings suggested the treatments reveal mechanism of action in neuroprotection, neuroregeneration, and inflammation modulation, which are critical in AD pathology. Ongoing trials also supported the safety and efficacy of the treatment strategies. However, translational medical study faces several challenges regarding large-scale production, optimization of protocols, and understanding biomarkers. The heterogeneity in secretome-based therapies administration have complicated the comparison of study outcomes and the translation of preclinical findings into clinical settings. Deeper understanding of the secretome's mechanisms of action, optimal dosing, and delivery methods are needed to maximize therapeutic outcomes.Conclusion: Despite secretome-based therapies hold significant promise for AD treatment, addressing the identified gaps and limitations is crucial for advancing these therapies from preclinical research to clinical practice.

Keywords

Alzheimer's disease; secretome; mesenchymal stem cells; exosomes; extracellular vesicles; neuroprotection; neuroregeneration

Subject

Medicine and Pharmacology, Neuroscience and Neurology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.